1. Scrip
  2. >>Business

Loxo Lays Out Plans For BTK Inhibitor LOXO-305 In CLL

Data At ASH Show Strong Post-Imbruvica Efficacy

 
• By Alaric DeArment

The company said investigators had been choosing the drug over Venclexta due to its less cumbersome administration, especially amid the COVID-19 pandemic.

Leukemia cell (blast cell)
Loxo Oncology at Lilly announced Phase I/II data for its BTK inhibitor in CLL • Source: Shutterstock

Phase I/II data for at Eli Lilly and Company’s non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, LOXO-305, show a high response rate among patients with chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) who previously received covalent BTK inhibitor therapies. That indicates the drug could add to a treatment space with few options and whose current occupants can be cumbersome to give.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

 
• By Mandy Jackson

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.

Amgen Under Pressure, But Seeing Gains Ahead Of Obesity Readouts

 
• By Mandy Jackson

MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.